Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025

Patel said retail generics became increasingly competitive around 2017–2018 due to a surge in FDA approvals and heavy buyer concentration, contributing to “a race to the bottom.” In response, Amneal reduced exposure to standard oral solids, which he said now represent roughly 25% of revenue, and increased emphasis on complex generics such as drug-device combinations, long-acting depot products, respiratory products, ready-to-use injectables, and ophthalmics.Co-CEO Chirag Patel said Amneal has evolved from a ...